Sharon Sim is a distinguished leader bringing a decade of comprehensive, on-the-ground operational and commercial expertise in Australia's clinical trial sector. Prior to founding Lexinto Biosolutions, Sharon spearheaded strategic business development for a prominent international bioanalytical laboratory, where she successfully guided numerous global biotechnology and pharmaceutical enterprises through the intricacies of the Australian clinical trial landscape to accelerate their global drug development timelines.

Over ten years of dedicated industry tenure, Sharon has cultivated an extensive and high-caliber ecosystem network within the Australian clinical research community. Her deeply rooted alliances span leading CROs, clinical trial sites, premium central laboratories, regulatory bodies, and critical supply chain stakeholders. This robust local positioning enables her to translate complex cross-border clinical requirements into seamless, high-yield operational executions.

Bridging academic rigor with high-level corporate acumen, Sharon holds a Master of Biotechnology and a Bachelor of Science (Honours) in Biochemistry and Molecular Biology from the University of Melbourne. Furthermore, as a graduate member of the Australian Institute of Company Directors (GAICD), she integrates stringent corporate governance, regulatory compliance, and risk management principles into every strategic client engagement.

At Lexinto Biosolutions, Sharon's mission is to eliminate market friction and logistical barriers for global drug innovators. Under her leadership, the firm delivers bespoke, end-to-end clinical anchoring solutions that combine deep local insights with institutional-grade standards, serving as the definitive strategic partner for biopharma companies expanding into Australia.